Novartis buys cancer-drug manufacturer Endocyte, FHIR boosters want the CMS and ONC to use their standard, and AI helps writers write.
Novartis buys cancer-drug manufacturer Endocyte, FHIR boosters want the CMS and ONC to use their standard, and AI helps writers write.